Diabetes, Obesity and Metabolism: Published on November, 2024TAKE-HOME MESSAGEThis review
synthesizes the available evidence on the use of SGLT2i (Empagliflozin, Dapagliflozin, Canagliflozin, Ertugliflozin)
and GLP-1 (Semaglutide, Liraglutide,
Dulaglutide, Exenatide) based therapies for T2D and provides a rationale for
their combination. The re...